Hydromorphon-Hcl Glenmark (Hydromorphone Hydrochloride)

Hydromorphone Hydrochloride is an opioid analgesic used to manage pain in several clinical settings.

• Moderate to severe acute pain: provides rapid analgesia for injuries, postoperative states, or trauma.
• Chronic cancer pain: helps control persistent pain associated with malignant disease.
• Post‑operative pain: reduces pain intensity after surgical procedures.

• Hydromorphone Hydrochloride acts as a full agonist at the μ‑opioid receptors in the central nervous system. Binding to these receptors inhibits the release of nociceptive neurotransmitters, leading to decreased perception of pain and increased sedation. The drug also modulates descending pain pathways, contributing to its potent analgesic effect.

Hydromorphon-Hcl Glenmark may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Constipation: reduced bowel motility.
• Drowsiness: increased sleepiness.
• Dizziness: sensation of light‑headedness.
• Dry mouth: reduced salivation.
• Sweating: excessive perspiration.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing.
• Severe hypotension: marked drop in blood pressure.
• Addiction or dependence: potential for misuse.
• Adrenal insufficiency: impaired cortisol response.
• Serotonin syndrome: when combined with serotonergic agents.
• Anaphylaxis: rare severe allergic reaction.

Before prescribing Hydromorphon-Hcl Glenmark, clinicians should consider several safety measures.

• Assess pain severity: confirm that opioid therapy is appropriate.
• Evaluate respiratory function: monitor for existing respiratory compromise.
• Review substance‑use history: identify risk of dependence.
• Adjust dose in renal/hepatic impairment: use lower starting doses.
• Monitor for sedation and confusion: especially in elderly patients.
• Store at ambient temperature: keep in the original container, protect from moisture.

Hydromorphon-Hcl Glenmark can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, alcohol): may cause profound respiratory depression.
• MAO inhibitors: increase risk of hypertensive crisis and serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise plasma hydromorphone levels.
• Respiratory depressants (e.g., barbiturates): potentiate breathing suppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Diuretics: can enhance hypotensive effects.
• Anticholinergic agents: may worsen constipation.
• SSRIs or SNRIs: increase risk of serotonin syndrome when combined.